Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rolando D. Z. Lyles"'
Autor:
Rolando D. Z. Lyles, Maria J. Martinez, Benjamin Sherman, Stephan Schürer, Kerry L. Burnstein
Publikováno v:
PLoS ONE, Vol 18, Iss 10 (2023)
Externí odkaz:
https://doaj.org/article/562f482a959f4d71a53881a9d5c32ce4
Autor:
Govindi J. Samaranayake, Clara I. Troccoli, Mai Huynh, Rolando D. Z. Lyles, Karen Kage, Andrew Win, Vishalakshi Lakshmanan, Deukwoo Kwon, Yuguang Ban, Steven Xi Chen, Enrique Rodriguez Zarco, Merce Jorda, Kerry L. Burnstein, Priyamvada Rai
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Identifying actionable components in castration–resistant prostate cancer (CRPC) is critical for the development of effective treatments. Here, the authors show that the inhibition of the redox-protective protein TRX1 decreases the growth of CRPC c
Externí odkaz:
https://doaj.org/article/d2ca0dbfe1e54bac82aeb4b72d117967
Autor:
Rolando D. Z. Lyles, Kerry L. Burnstein, Stephanie Peacock, Jonathan Weitz, Pablo S. Magani, Meghan A. Rice, Fiorella Magani, Maria J. Martinez, Ann M. Greene
Publikováno v:
Molecular Cancer Research. 15:1469-1480
Castration-resistant prostate cancer (CRPC) progresses rapidly and is incurable. Constitutively active androgen receptor splice variants (AR-Vs) represent a well-established mechanism of therapeutic resistance and disease progression. These variants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f5b1113225f1035f07d15f63ae4cf7
https://doi.org/10.1158/1541-7786.mcr-17-0280
https://doi.org/10.1158/1541-7786.mcr-17-0280
Autor:
Clara I. Troccoli, Andrew Win, Kerry L. Burnstein, Rolando D. Z. Lyles, Merce Jorda, Priyamvada Rai, Steven Xi Chen, Vishalakshi Lakshmanan, Karen Kage, Mai Huynh, Govindi J. Samaranayake, Enrique Rodriguez Zarco, Deukwoo Kwon, Yuguang Ban
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Nature Communications
Nature Communications
Androgen deprivation (AD) therapy failure leads to terminal and incurable castration-resistant prostate cancer (CRPC). We show that the redox-protective protein thioredoxin-1 (TRX1) increases with prostate cancer progression and in androgen-deprived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2beed9cebb10f1d79b00a26341a82cd7
https://doaj.org/article/d2ca0dbfe1e54bac82aeb4b72d117967
https://doaj.org/article/d2ca0dbfe1e54bac82aeb4b72d117967
Autor:
Nikita S. Sharma, Yuguang Ban, Clara I. Troccoli, Priyamvada Rai, Rolando D. Z. Lyles, Govindi J. Samaranayake, Deukwoo Kwon, Steven Xi Chen, Mai Huynh, Kerry L. Burnstein, Sulagna Banerjee, Merce Jorda
Publikováno v:
Free Radical Biology and Medicine. 128:S75
Castration-resistant prostate cancer (CRPC) arises from a failure of standard-of-care androgen deprivation (AD) therapy to suppress emergence of castration-resistant variants from the original AD-responsive prostate cancer (ADPC). Identification of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b246c1e454ffa9c0c683c444500ab3a1
https://doi.org/10.1016/j.freeradbiomed.2018.10.163
https://doi.org/10.1016/j.freeradbiomed.2018.10.163
Autor:
Mai Q. Huynh, Priyamvada Rai, Deukwoo Kwon, Govindi J. Samaranayake, Yuguang Ban, Kerry L. Burnstein, Merce Jorda, Clara I. Troccoli, Rolando D. Z. Lyles, Steven Xi Chen
Publikováno v:
Cancer Research. 78:B032-B032
Androgen deprivation therapy (ADT) initially suppresses prostate cancer (PC) progression. However, castration-resistant PC (CRPC) cells inevitably emerge, resulting in incurable disease. We recently demonstrated that AD produces a form of cellular se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3baed521c2c617d5b3a3737f9c926ddc
https://doi.org/10.1158/1538-7445.prca2017-b032
https://doi.org/10.1158/1538-7445.prca2017-b032